Sonoma Pharmaceuticals, Inc.(SNOA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Sonoma Pharmaceuticals, Inc. (SNOA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SNOA at 36.2/100 on a 32-signal composite quality model, placing it at rank #2,277 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Sonoma Pharmaceuticals, Inc. reports quarterly revenue of $6.4M, net income of $-330.0K, free cash flow of $-651.0K. Top institutional holders of SNOA by reported 13-F value include RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. SNOA trades on the Nasdaq exchange and files with the SEC under CIK 1367083. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sonoma Pharmaceuticals, Inc. directly from SEC EDGAR.
AI Quality Score
36.2/100
AI Rank
#2,277
Revenue
$6.4M
Net Income
$-330.0K
Free Cash Flow
$-651.0K
SNOA key financials by period
Sonoma Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2026
10-K
$19.5M
$-3.2M
-12.6%
FY 2025
10-K
$14.3M
$-3.5M
-26.0%
FY 2024
10-K
$12.7M
$-4.8M
-36.9%
FY 2023
10-K
$13.3M
$-5.2M
-34.4%
FY 2022
10-K
$12.6M
$-5.1M
-46.6%
FY 2021
10-K
$18.6M
$-4.0M
-18.5%
Institutions holding SNOA
Institutional investors reporting a position in Sonoma Pharmaceuticals, Inc. on SEC Form 13F.
